

Brian I Carr

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5320619/brian-i-carr-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

291
papers

10,330
citations

50
h-index

90
g-index

306
ext. papers

11,164
ext. citations

4.8
avg, IF

6
L-index

#	Paper	IF	Citations
291	Bringing It All Together 2022 , 447-460		
290	Inflammation, Chronic Disease, and Cancer: Is Psychological Distress the Common Thread? 2022 , 1-19		
289	EMT and Inflammation: Crossroads in HCC.. <i>Journal of Gastrointestinal Cancer</i> , 2022 , 1	1.6	0
288	Can the Limits of Liver Transplantation Be Expanded in Perihilar Cholangiocarcinoma?. <i>Journal of Gastrointestinal Cancer</i> , 2021 , 1	1.6	
287	CRP is a superior and prognostically significant inflammation biomarker for hepatocellular cancer patients treated by liver transplantation. <i>Clinical Practice (London, England)</i> , 2021 , 18, 1626-1632	3	1
286	A Combination of Blood Lymphocytes and AST Levels Distinguishes Patients with Small Hepatocellular Carcinomas from Non-cancer Patients. <i>Journal of Gastrointestinal Cancer</i> , 2021 , 1	1.6	0
285	Hepatitis B Before and After Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2021 , 1	1.6	0
284	Relationships Between Indices of Tumor Aggressiveness in Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2021 , 52, 1340	1.6	1
283	Serum levels of inflammatory markers CRP, ESR and albumin in relation to survival for patients with hepatocellular carcinoma. <i>International Journal of Clinical Practice</i> , 2021 , 75, e13593	2.9	5
282	A Recipient and Donor Both Have COVID-19 Disease. Should We Perform a Liver Transplant?. <i>Journal of Gastrointestinal Cancer</i> , 2021 , 52, 1143-1147	1.6	6
281	Identification of Clinical Phenotypes and Related Survival in Patients with Large HCCs. <i>Cancers</i> , 2021 , 13,	6.6	2
280	Changes in hepatocellular carcinoma aggressiveness characteristics with an increase in tumor diameter. <i>International Journal of Biological Markers</i> , 2021 , 36, 54-61	2.8	5
279	Microscopic Portal Vein Invasion in Relation to Tumor Focality and Dimension in Patients with Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2021 , 1	3.3	0
278	Overview of Clinical HCC and Its Management 2021 , 111-126		
277	Biological Aspects of HCC 2021 , 3-11		1
276	A simple 2-parameter blood test alert for the presence of small hepatocellular carcinomas.. <i>Clinical Practice (London, England)</i> , 2021 , 18, 1804-1809	3	
275	Gamma glutamyl transpeptidase as a prognostic biomarker in hepatocellular cancer patients especially with >5 cm tumors, treated by liver transplantation. <i>International Journal of Biological Markers</i> , 2020 , 35, 91-95	2.8	10

274	Liver Transplantation for Hepatocellular Carcinoma: Malatya Experience and Proposals for Expanded Criteria. <i>Journal of Gastrointestinal Cancer</i> , 2020 , 51, 998-1005	1.6	25
273	Microscopic vascular invasion by hepatocellular carcinoma in liver transplant patients. <i>Clinical Practice (London, England)</i> , 2020 , 17, 1497-1505	3	4
272	Liver transplant for large hepatocellular carcinoma in Malatya: The role of gamma glutamyl transferase and alpha-fetoprotein, a retrospective cohort study. <i>World Journal of Gastrointestinal Surgery</i> , 2020 , 12, 520-533	2.4	5
271	Platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios predict tumor size and survival in HCC patients: Retrospective study. <i>Annals of Medicine and Surgery</i> , 2020 , 58, 167-171	2	5
270	Trends in Tumor Indices in Relation to Increased Hepatocellular Carcinoma Size: Evidence for Tumor Evolution as a Function of Growth. <i>Journal of Gastrointestinal Cancer</i> , 2020 , 51, 1215-1219	1.6	5
269	Portal Vein Thrombosis and Markers of Inflammation in Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2020 , 51, 1141-1147	1.6	8
268	Inflammatory markers C-reactive protein and PLR in relation to HCC characteristics. <i>Journal of Translational Science</i> , 2019 , 5,	2.2	16
267	Review of therapies for intermediate and advanced stage hepatocellular carcinoma, not suitable for curative therapies: a rapidly changing landscape. <i>Hepatoma Research</i> , 2019 , 5,	4.3	1
266	C-Reactive Protein and Platelet-Lymphocyte Ratio as Potential Tumor Markers in Low-Alpha-Fetoprotein Hepatocellular Carcinoma. <i>Oncology</i> , 2019 , 96, 25-32	3.6	11
265	Macroscopic Portal Vein Thrombosis in HCC Patients. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018 , 2018, 3120185	2.8	14
264	Plasma cholesterol and lipoprotein levels in relation to tumor aggressiveness and survival in HCC patients. <i>International Journal of Biological Markers</i> , 2018 , 33, 423-431	2.8	18
263	Characteristics of Hepatocellular Carcinoma Aggressiveness Factors in Turkish Patients. <i>Oncology</i> , 2018 , 94, 116-124	3.6	14
262	Analysis of aggressiveness factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization. <i>World Journal of Gastroenterology</i> , 2018 , 24, 1641-1649	5.6	6
261	HCC with low- and normal-serum alpha-fetoprotein levels. <i>Clinical Practice (London, England)</i> , 2018 , 15, 453-464	3	29
260	C-reactive protein and hepatocellular carcinoma: analysis of its relationships to tumor factors. <i>Clinical Practice (London, England)</i> , 2018 , 15, 625-634	3	10
259	Pleiotropic Effects of Heparins: From Clinical Applications to Molecular Mechanisms in Hepatocellular Carcinoma. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018 , 2018, 7568742	2.8	2
258	Role of Albumin in Growth Inhibition in Hepatocellular Carcinoma. <i>Oncology</i> , 2017 , 93, 136-142	3.6	42
257	Validation of a Liver Index and Its Significance for HCC Aggressiveness. <i>Journal of Gastrointestinal Cancer</i> , 2017 , 48, 262-266	1.6	3

256	The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017 , 66, 338-346	13.4	191
255	Serum albumin levels in relation to tumor parameters in hepatocellular carcinoma patients. <i>International Journal of Biological Markers</i> , 2017 , 32, e391-e396	2.8	39
254	IGF-1R tyrosine kinase inhibitors and Vitamin K1 enhance the antitumor effects of Regorafenib in HCC cell lines. <i>Oncotarget</i> , 2017 , 8, 103465-103476	3.3	18
253	New Developments in Orthotopic Liver Transplant for Hepatocellular Carcinoma. <i>Experimental and Clinical Transplantation</i> , 2017 , 15, 1-6	0.8	
252	HCC and Its Microenvironment 2016 , 163-166		
251	A systemic evolutionary approach to cancer: Hepatocarcinogenesis as a paradigm. <i>Medical Hypotheses</i> , 2016 , 93, 132-7	3.8	8
250	Low Alpha-Fetoprotein Levels Are Associated with Improved Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis. <i>Digestive Diseases and Sciences</i> , 2016 , 61, 937-47	4	16
249	A Hepatocellular Carcinoma Aggressiveness Index and Its Relationship to Liver Enzyme Levels. <i>Oncology</i> , 2016 , 90, 215-20	3.6	31
248	Medical Therapy of HCC 2016 , 489-512		1
247	Bringing It All Together 2016 , 579-584		
246	An HCC Aggressiveness Index and Blood GTP, Bilirubin and Platelet Levels. <i>Journal of Integrative Oncology</i> , 2016 , 5,		6
245	A Liver Index and its Relationship to Indices of HCC Aggressiveness. <i>Journal of Integrative Oncology</i> , 2016 , 5,		22
244	Hepatocellular Carcinoma Extrahepatic Metastasis in Relation to Tumor Size and Alkaline Phosphatase Levels. <i>Oncology</i> , 2016 , 90, 136-42	3.6	29
243	MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015 , 9, 993-1003	4.2	23
242	Evaluation of total hepatocellular cancer lifespan, including both clinically evident and preclinical development, using combined network phenotyping strategy and fisher information analysis. <i>Seminars in Oncology</i> , 2015 , 42, 339-46	5.5	1
241	A comparison of patients with hepatitis B- or hepatitis C-based advanced-stage hepatocellular carcinoma. <i>Seminars in Oncology</i> , 2015 , 42, 309-15	5.5	6
240	Validation of the Concept of a Common Typical Time of Disease Duration for Hepatocellular Carcinoma Patients Using the Fisher Information Processing of Tumor Imaging Results Combined With Network Phenotyping Strategy Quantification of Individual Patient Clinical Profile Patterns. <i>Seminars in Oncology</i> , 2015 , 42, 672-8	5.5	
239	Modulation of sensitivity and resistance to multikinase inhibitors by microenvironmental platelet factors in HCC. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 2773-80	4	15

238	Resistance to multikinase inhibitor actions mediated by insulin like growth factor-1. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015 , 34, 90	12.8	17
237	Angiotensin receptor blockers improve survival outcomes after radiofrequency ablation in hepatocarcinoma patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015 , 30, 1643-50	4	40
236	Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 75, 1237-1245	3.5	13
235	Serum ferritin as a new prognostic factor in hepatocellular carcinoma patients treated with radiofrequency ablation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014 , 29, 1905-10	4	57
234	Post-recurrence survival in hepatocellular carcinoma after percutaneous radiofrequency ablation. <i>Digestive and Liver Disease</i> , 2014 , 46, 1014-9	3.3	39
233	Understanding Liver Cancer 2014 ,		1
232	A systematic review of randomized controlled trials testing the efficacy of psychosocial interventions for gastrointestinal cancers. <i>Journal of Gastrointestinal Cancer</i> , 2014 , 45, 181-9	1.6	8
231	Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines. <i>BMC Cancer</i> , 2014 , 14, 351	4.8	27
230	Macro- and micro-environmental factors in clinical hepatocellular cancer. <i>Seminars in Oncology</i> , 2014 , 41, 185-94	5.5	14
229	Association of abnormal plasma bilirubin with aggressive hepatocellular carcinoma phenotype. <i>Seminars in Oncology</i> , 2014 , 41, 252-8	5.5	28
228	Identification of two clinical hepatocellular carcinoma patient phenotypes from results of standard screening parameters. <i>Seminars in Oncology</i> , 2014 , 41, 406-414	5.5	11
227	Platelet-related phenotypic patterns in hepatocellular carcinoma patients. <i>Seminars in Oncology</i> , 2014 , 41, 415-21	5.5	24
226	Low alpha-fetoprotein HCC and the role of GGTP. <i>International Journal of Biological Markers</i> , 2014 , 29, e395-402	2.8	15
225	Significance of platelet and AFP levels and liver function parameters for HCC size and survival. <i>International Journal of Biological Markers</i> , 2014 , 29, e215-23	2.8	27
224	Platelet extracts induce growth, migration and invasion in human hepatocellular carcinoma in vitro. <i>BMC Cancer</i> , 2014 , 14, 43	4.8	80
223	Features of massive hepatocellular carcinomas. <i>European Journal of Gastroenterology and Hepatology</i> , 2014 , 26, 101-8	2.2	12
222	Modulation of Doxorubicin mediated growth inhibition of hepatocellular carcinoma cells by platelet lysates. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2014 , 14, 1154-60	2.2	6
221	The Whole Patient Setting 2014 , 45-46		

220 Introduction to hepatocellular carcinoma: A tale of two diseases **2014**, 1-16

219 Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. *Cancer*, **2013**, 119, 380-7 6.4 82

218 Clinical characteristics and survival of European patients with resectable large hepatocellular carcinomas. *Journal of Gastrointestinal Cancer*, **2013**, 44, 329-35 1.6 4

217 Systemic treatment of gastrointestinal cancer in elderly patients. *Journal of Gastrointestinal Cancer*, **2013**, 44, 22-32 1.6 18

216 Thrombocytosis and hepatocellular carcinoma. *Digestive Diseases and Sciences*, **2013**, 58, 1790-6 4 49

215 Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. *Journal of Cellular Physiology*, **2013**, 228, 292-7 7 56

214 Reversibility of regorafenib effects in hepatocellular carcinoma cells. *Cancer Chemotherapy and Pharmacology*, **2013**, 72, 869-77 3.5 11

213 Effects of low concentrations of regorafenib and sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro. *Journal of Cellular Physiology*, **2013**, 228, 1344-50 7 41

212 Hepatocellular carcinoma size: platelets, α -glutamyl transpeptidase, and alkaline phosphatase. *Oncology*, **2013**, 85, 153-9 3.6 29

211 HCC and its microenvironment. *Hepato-Gastroenterology*, **2013**, 60, 1433-7 8

210 Phenotypic Categorization and Profiles of Small and Large Hepatocellular Carcinomas **2013**, Suppl 12, 7

209 Bringing It All Together **2013**, 395-406

208 Cell membrane and cytoplasmic epidermal growth factor receptor expression in pancreatic ductal adenocarcinoma. *Medical Oncology*, **2012**, 29, 134-9 3.7 15

207 Some new approaches to the management of hepatocellular carcinoma. *Seminars in Oncology*, **2012**, 39, 369-73 5.5 6

206 Peripheral blood lymphocyte depletion after hepatic arterial ^{90}Y trium microsphere therapy for hepatocellular carcinoma. *International Journal of Radiation Oncology Biology Physics*, **2012**, 82, 1179-84 4 15

205 Developments in liver transplantation for hepatocellular carcinoma. *Seminars in Oncology*, **2012**, 39, 510-24 20

204 Small hepatocellular carcinomas and thrombocytopenia. *Oncology*, **2012**, 83, 331-8 3.6 19

203 Thrombocytopenia in relation to tumor size in patients with hepatocellular carcinoma. *Oncology*, **2012**, 83, 339-45 3.6 30

202	Hepatic artery chemoembolization for hepatocellular carcinoma recurrence confined to the transplanted liver. <i>Case Reports in Oncology</i> , 2012 , 5, 506-10	1	5
201	Identification of two HCC phenotypes based on thrombocytopenia.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e14720-e14720	2.2	
200	Prospective randomized trial of hepatic artery chemotherapy with cisplatin and doxorubicin, with or without lipiodol in the treatment of advanced stage hepatocellular carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2011 , 45, e87-91	3	6
199	Differential effects of vitamin K1 on AFP and DCP levels in patients with unresectable HCC and in HCC cell lines. <i>Digestive Diseases and Sciences</i> , 2011 , 56, 1876-83	4	13
198	Small HCCs identified by screening. <i>Digestive Diseases and Sciences</i> , 2011 , 56, 3078-85	4	8
197	Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients. <i>Medical Oncology</i> , 2011 , 28 Suppl 1, S286-90	3.7	53
196	c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition. <i>Cancer Biology and Therapy</i> , 2011 , 12, 531-8	4.6	19
195	Small hepatocellular carcinoma in Chinese patients. <i>Hepato-Gastroenterology</i> , 2011 , 58, 1334-42		7
194	Naturally occurring K vitamins inhibit pancreatic cancer cell survival through a caspase-dependent pathway. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010 , 25, 738-44	4	16
193	Low alpha-fetoprotein hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010 , 25, 1543-9	4	26
192	Economic evaluation of sorafenib in unresectable hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010 , 25, 1739-46	4	40
191	Pain at presentation and survival in hepatocellular carcinoma. <i>Journal of Pain</i> , 2010 , 11, 988-93	5.2	13
190	HCC in older patients. <i>Digestive Diseases and Sciences</i> , 2010 , 55, 3584-90	4	8
189	Network-based analysis of survival for unresectable hepatocellular carcinoma. <i>Seminars in Oncology</i> , 2010 , 37, 170-81	5.5	13
188	Regional hepatic therapy for cancer. <i>Seminars in Oncology</i> , 2010 , 37, 82	5.5	
187	Cancer-related symptom clusters, eosinophils, and survival in hepatobiliary cancer: an exploratory study. <i>Journal of Pain and Symptom Management</i> , 2010 , 39, 859-71	4.8	35
186	Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. <i>Cancer</i> , 2010 , 116, 1305-14	6.4	147
185	Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo. <i>International Journal of Cancer</i> , 2010 , 127, 2949-58	7.5	40

184	Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways. <i>Journal of Cellular Physiology</i> , 2010 , 224, 112-9	7	17
183	Involvement of receptor tyrosine phosphatase DEP-1 mediated PI3K-cofilin signaling pathway in sorafenib-induced cytoskeletal rearrangement in hepatoma cells. <i>Journal of Cellular Physiology</i> , 2010 , 224, 559-65	7	17
182	HCC in young adults. <i>Hepato-Gastroenterology</i> , 2010 , 57, 436-40		3
181	Significance of increased serum GGTP levels in HCC patients. <i>Hepato-Gastroenterology</i> , 2010 , 57, 869-74		12
180	Chemoembolization for unresectable hepatocellular carcinoma in patients with or without portal vein thrombosis. <i>Hepato-Gastroenterology</i> , 2010 , 57, 1375-81		6
179	Involvement of ATM-mediated Chk1/2 and JNK kinase signaling activation in HKH40A-induced cell growth inhibition. <i>Journal of Cellular Physiology</i> , 2009 , 221, 213-20	7	20
178	Growth inhibition of hepatocellular carcinoma cells in vitro and in vivo by the 8-methoxy analog of WMC79. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 63, 769-78	3.5	12
177	Systematic prediction of human membrane receptor interactions. <i>Proteomics</i> , 2009 , 9, 5243-55	4.8	16
176	Hepatobiliary effects of 90yttrium microsphere therapy for unresectable hepatocellular carcinoma. <i>Human Pathology</i> , 2009 , 40, 125-34	3.7	22
175	Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study. <i>Hepatology International</i> , 2009 , 4, 396-405	8.8	31
174	Medical Therapy of HCC 2009 , 527-568		
173	Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a case cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008 , 23, 1259-66	4	29
172	Measuring post-traumatic growth in people diagnosed with hepatobiliary cancer: directions for future research. <i>Oncology Nursing Forum</i> , 2008 , 35, 643-50	1.7	20
171	Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. <i>Hepatology</i> , 2008 , 47, 71-81	11.2	44 ⁸
170	Chemo-embolization for unresectable hepatocellular carcinoma with different sizes of embolization particles. <i>Digestive Diseases and Sciences</i> , 2008 , 53, 1400-4	4	26
169	2-Methoxyestradiol inhibits hepatocellular carcinoma cell growth by inhibiting Cdc25 and inducing cell cycle arrest and apoptosis. <i>Cancer Chemotherapy and Pharmacology</i> , 2008 , 62, 831-40	3.5	16
168	Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience. <i>Journal of Gastrointestinal Surgery</i> , 2008 , 12, 129-37	3.3	103
167	Gender-based outcomes differences in unresectable hepatocellular carcinoma. <i>Hepatology International</i> , 2008 , 2, 95-101	8.8	27

166	Assessing spiritual growth and spiritual decline following a diagnosis of cancer: reliability and validity of the spiritual transformation scale. <i>Psycho-Oncology</i> , 2008 , 17, 112-21	3.9	74
165	Integrin alpha5-induced EGFR activation by prothrombin triggers hepatocyte apoptosis via the JNK signaling pathway. <i>Journal of Cellular Physiology</i> , 2008 , 216, 551-7	7	12
164	Treatment before liver transplantation for HCC. <i>Annals of Surgical Oncology</i> , 2008 , 15, 993-1000	3.1	95
163	Abstract A52: Vitamin K1 enhances sorafenib effects on HCC and induces apoptosis: A nontoxic prevention strategy 2008 ,		2
162	Grb2-associated binder-1 plays a central role in the hepatocyte growth factor enhancement of hepatoma growth inhibition by K vitamin analog compound 5. <i>Hepatology</i> , 2007 , 46, 2003-13	11.2	6
161	Fluorinated NSC as a Cdc25 inhibitor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007 , 17, 2351-4	2.9	31
160	A simple prognostic scoring system for patients with unresectable hepatocellular carcinoma treated by chemo-embolization. <i>Cancer Detection and Prevention</i> , 2007 , 31, 154-60		18
159	alpha-Thrombin inhibits DNA synthesis in rat hepatocytes but not in hepatoma cells by receptor activation and proteolysis. <i>Molecular and Cellular Biochemistry</i> , 2007 , 304, 189-97	4.2	1
158	Health-related quality of life: Hepatocellular carcinoma, chronic liver disease, and the general population. <i>Quality of Life Research</i> , 2007 , 16, 203-15	3.7	50
157	Posttraumatic growth, immunity and survival in patients with hepatoma. <i>Digestive Diseases and Sciences</i> , 2007 , 52, 2452-9	4	34
156	Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. <i>Digestive Diseases and Sciences</i> , 2007 , 52, 776-82	4	105
155	Causes of death in patients with unresectable hepatocellular carcinoma. <i>Digestive Diseases and Sciences</i> , 2007 , 52, 3285-9	4	45
154	Growth inhibitory actions of prothrombin on normal hepatocytes: influence of matrix. <i>Cell Biology International</i> , 2007 , 31, 929-38	4.5	6
153	Prognostic models in hepatocellular carcinoma (HCC) and statistical methodologies behind them. <i>Current Pharmaceutical Design</i> , 2007 , 13, 1527-32	3.3	7
152	Preliminary results of an individually tailored psychosocial intervention for patients with advanced hepatobiliary carcinoma. <i>Journal of Psychosocial Oncology</i> , 2007 , 25, 19-42	2.8	31
151	Depression, immunity, and survival in patients with hepatobiliary carcinoma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2397-405	2.2	115
150	Fluorinated Cpd 5, a pure arylating K-vitamin derivative, inhibits human hepatoma cell growth by inhibiting Cdc25 and activating MAPK. <i>Biochemical Pharmacology</i> , 2006 , 72, 1217-27	6	28
149	Phosphorylation regulates Myc expression via prolonged activation of the mitogen-activated protein kinase pathway. <i>Journal of Cellular Physiology</i> , 2006 , 208, 133-40	7	15

148	H32, a non-quinone sulfone analog of vitamin K3, inhibits human hepatoma cell growth by inhibiting Cdc25 and activating ERK. <i>Cancer Biology and Therapy</i> , 2006 , 5, 1340-7	4.6	19
147	Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma. <i>Annals of Oncology</i> , 2006 , 17, 304-12	10.3	73
146	PM-20, a novel inhibitor of Cdc25A, induces extracellular signal-regulated kinase 1/2 phosphorylation and inhibits hepatocellular carcinoma growth in vitro and in vivo. <i>Molecular Cancer Therapeutics</i> , 2006 , 5, 1511-9	6.1	39
145	Antitumor activity of JS-K [O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazene-1-ium-1,2-diolate] and related O2-aryl diazeniumdiolates in vitro and in vivo. <i>Journal of Medicinal Chemistry</i> , 2006 , 49, 4356-66	8.3	93
144	Outcome of 1000 liver cancer patients evaluated at the UPMC Liver Cancer Center. <i>Journal of Gastrointestinal Surgery</i> , 2006 , 10, 63-8	3.3	20
143	Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. <i>Journal of Vascular and Interventional Radiology</i> , 2005 , 16, 205-13	2.4	152
142	Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2005 , 16, 195-203	2.4	105
141	Vitamin K analog (compound 5) induces apoptosis in human hepatocellular carcinoma independent of the caspase pathway. <i>Anti-Cancer Drugs</i> , 2005 , 16, 837-44	2.4	3
140	Hepatocyte growth factor enhances protein phosphatase Cdc25A inhibitor compound 5-induced hepatoma cell growth inhibition via Akt-mediated MAPK pathway. <i>Journal of Cellular Physiology</i> , 2005 , 203, 510-9	7	11
139	Cdc25A and ERK interaction: EGFR-independent ERK activation by a protein phosphatase Cdc25A inhibitor, compound 5. <i>Journal of Cellular Physiology</i> , 2005 , 204, 437-44	7	34
138	Sexual functioning in patients with hepatocellular carcinoma. <i>Cancer</i> , 2005 , 104, 2234-43	6.4	16
137	Sequential FDG PET/CT in 90Y microsphere treatment of unresectable colorectal liver metastases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005 , 32, 723	8.8	11
136	90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005 , 32, 778-87	8.8	57
135	The effects of hepatic artery chemotherapy on viral hepatitis in patients with hepatocellular carcinoma. <i>Digestive Diseases and Sciences</i> , 2005 , 50, 331-5	4	13
134	Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy. <i>Investigational New Drugs</i> , 2005 , 23, 235-9	4.3	34
133	Proxy ratings of health related quality of life in patients with hepatocellular carcinoma. <i>Quality of Life Research</i> , 2005 , 14, 1025-33	3.7	28
132	Novel hydroxyl naphthoquinones with potent Cdc25 antagonizing and growth inhibitory properties. <i>Molecular Cancer Therapeutics</i> , 2005 , 4, 595-602	6.1	25
131	Medical Therapy of Hepatocellular Carcinoma 2005 , 233-264		

130	NAD(P)H:quinone oxidoreductase-1-dependent and -independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004 , 309, 64-70	4.7	37
129	Inhibition of rat liver regeneration after partial hepatectomy and induction of ERK phosphorylation by Cpd 5, a K vitamin-based anticancer compound. <i>Carcinogenesis</i> , 2004 , 25, 2345-51	4.6	2
128	Quality of life in patients diagnosed with primary hepatocellular carcinoma: hepatic arterial infusion of Cisplatin versus 90-Yttrium microspheres (Therasphere). <i>Psycho-Oncology</i> , 2004 , 13, 73-9	3.9	80
127	Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. <i>Liver Transplantation</i> , 2004 , 10, S107-10	4.5	219
126	Fluorinated quinoid inhibitor: possible "pure" arylator predicted by the simple theoretical calculation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004 , 14, 4103-5	2.9	28
125	Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. <i>Gastroenterology</i> , 2004 , 127, S194-205	13.3	269
124	Hepatocellular carcinoma: current management and future trends. <i>Gastroenterology</i> , 2004 , 127, S218-24	13.3	196
123	Involvement of c-Myc in growth inhibition of Hep 3B human hepatoma cells by a vitamin K analog. <i>Journal of Hepatology</i> , 2004 , 41, 823-9	13.4	6
122	The role of psychosocial factors in the progression of hepatocellular carcinoma. <i>Medical Hypotheses</i> , 2004 , 62, 86-94	3.8	13
121	Characteristics of hepatocellular carcinoma in a high arsenicism area in Taiwan: a case-control study. <i>Journal of Occupational and Environmental Medicine</i> , 2004 , 46, 437-41	2	13
120	Cell Division Cycle 25 (Cdc25) Phosphatase Inhibitors as Antitumor Agents. <i>Drug Design Reviews Online</i> , 2004 , 1, 123-132		3
119	Antitumor and anticarcinogenic actions of Cpd 5: a new class of protein phosphatase inhibitor. <i>Carcinogenesis</i> , 2003 , 24, 411-6	4.6	16
118	To transplant, or not to transplant?. <i>Liver Transplantation</i> , 2003 , 9, 533-4	4.5	
117	Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma. <i>Cancer</i> , 2003 , 97, 1042-50	6.4	87
116	JS-K, a novel non-ionic diazeniumdiolate derivative, inhibits Hep 3B hepatoma cell growth and induces c-Jun phosphorylation via multiple MAP kinase pathways. <i>Journal of Cellular Physiology</i> , 2003 , 197, 426-34	7	51
115	Binding and inhibition of Cdc25 phosphatases by vitamin K analogues. <i>Biochemistry</i> , 2003 , 42, 10490-7	3.2	41
114	A Cdc25A antagonizing K vitamin inhibits hepatocyte DNA synthesis in vitro and in vivo. <i>Journal of Molecular Biology</i> , 2003 , 326, 721-35	6.5	16
113	Differential effects of two growth inhibitory K vitamin analogs on cell cycle regulating proteins in human hepatoma cells. <i>Life Sciences</i> , 2003 , 72, 2769-84	6.8	16

112	Persistent ERK phosphorylation negatively regulates cAMP response element-binding protein (CREB) activity via recruitment of CREB-binding protein to pp90RSK. <i>Journal of Biological Chemistry</i> , 2003 , 278, 11138-44	5.4	62
111	EGFR-independent activation of ERK1/2 mediates growth inhibition by a PTPase antagonizing K-vitamin analog. <i>Journal of Cellular Physiology</i> , 2002 , 190, 356-64	7	16
110	Transient and sustained ERK phosphorylation and nuclear translocation in growth control. <i>Journal of Cellular Physiology</i> , 2002 , 192, 151-9	7	66
109	K vitamins, PTP antagonism, and cell growth arrest. <i>Journal of Cellular Physiology</i> , 2002 , 193, 263-74	7	36
108	Identification of epidermal growth factor receptor as a target of Cdc25A protein phosphatase. <i>Journal of Biological Chemistry</i> , 2002 , 277, 19470-5	5.4	39
107	Induction of apoptosis via mitogen-activated protein kinase pathway by a K vitamin analog in rat hepatocytes. <i>Journal of Hepatology</i> , 2002 , 36, 85-92	13.4	15
106	Vitamin K uptake in hepatocytes and hepatoma cells. <i>Life Sciences</i> , 2002 , 70, 2085-100	6.8	18
105	Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. <i>Journal of Vascular and Interventional Radiology</i> , 2002 , 13, S223-9	2.4	203
104	Hepatic artery chemoembolization for advanced stage HCC: experience of 650 patients. <i>Hepato-Gastroenterology</i> , 2002 , 49, 79-86		21
103	Continuous infusion prochlorperazine: pharmacokinetics, antiemetic efficacy, and feasibility of high-dose therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2001 , 47, 327-32	3.5	8
102	Clinical significance of elevated alpha-fetoprotein in adults and children. <i>Digestive Diseases and Sciences</i> , 2001 , 46, 1709-13	4	18
101	Hepatocellular carcinomas in native livers from patients treated with orthotopic liver transplantation: biologic and therapeutic implications. <i>Hepatology</i> , 2001 , 34, 502-10	11.2	52
100	Spatial analysis of key signaling proteins by high-content solid-phase cytometry in Hep3B cells treated with an inhibitor of Cdc25 dual-specificity phosphatases. <i>Journal of Biological Chemistry</i> , 2001 , 276, 20544-50	5.4	35
99	Mechanism of novel vitamin K analog induced growth inhibition in human hepatoma cell line. <i>Journal of Hepatology</i> , 2001 , 34, 676-82	13.4	19
98	Expression of the Hoxa-13 gene correlates to hepatitis B and C virus associated HCC. <i>Biochemical and Biophysical Research Communications</i> , 2001 , 281, 1041-4	3.4	14
97	Tumor cell growth inhibition and extracellular signal-regulated kinase (ERK) phosphorylation by novel K vitamins. <i>Journal of Molecular Biology</i> , 2001 , 314, 765-72	6.5	26
96	Involvement of hepatocyte epidermal growth factor receptor mediated activation of mitogen-activated protein kinase signaling pathways in response to growth inhibition by a novel K vitamin. <i>Journal of Cellular Physiology</i> , 2000 , 183, 338-46	7	25
95	Growth inhibition and protein tyrosine phosphorylation in MCF 7 breast cancer cells by a novel K vitamin. <i>Journal of Cellular Physiology</i> , 2000 , 185, 386-93	7	27

94	Critical role of extracellular signal-regulated kinase (ERK) phosphorylation in novel vitamin K analog-induced cell death. <i>Japanese Journal of Cancer Research</i> , 2000 , 91, 1250-7		12
93	Liver transplantation for hepatocellular carcinoma: a proposal of a prognostic scoring system. <i>Journal of the American College of Surgeons</i> , 2000 , 191, 389-94	4.4	178
92	Prognostic significance of arterial phase CT for prediction of response to transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: a retrospective analysis. <i>American Journal of Roentgenology</i> , 2000 , 175, 1665-72	5.4	48
91	Liver transplantation and chemotherapy for hepatoblastoma and hepatocellular cancer in childhood and adolescence. <i>Journal of Pediatrics</i> , 2000 , 136, 795-804	3.6	143
90	P53 but not p16INK4a induces growth arrest in retinoblastoma-deficient hepatocellular carcinoma cells. <i>Journal of Hepatology</i> , 2000 , 33, 254-65	13.4	4
89	Use of intrahepatic chemotherapy to treat advanced pediatric hepatic malignancies. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2000 , 30, 137-44	2.8	18
88	Inhibition of hepatoma cell growth in vitro by arylating and non-arylated K vitamin analogs. Significance of protein tyrosine phosphatase inhibition. <i>Journal of Biological Chemistry</i> , 1999 , 274, 34803-10	5.4	36
87	Radiotherapy and multimodality management of cholangiocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999 , 44, 121-6	4	59
86	ERCP and stent therapy for progressive jaundice in hepatocellular carcinoma: which patients benefit, which patients don't?. <i>Digestive Diseases and Sciences</i> , 1999 , 44, 1298-302	4	17
85	The inhibitory effect of interleukin 1beta on rat hepatocyte DNA synthesis is mediated by nitric oxide. <i>Hepatology</i> , 1998 , 28, 430-5	11.2	27
84	Changes in TGF-beta receptors of rat hepatocytes during primary culture and liver regeneration: increased expression of TGF-beta receptors associated with increased sensitivity to TGF-beta-mediated growth inhibition. <i>Journal of Cellular Physiology</i> , 1998 , 176, 612-23	7	35
83	Transforming growth factor alpha (TGFalpha) in hepatocellular carcinomas and adjacent hepatic parenchyma. <i>Human Pathology</i> , 1998 , 29, 228-34	3.7	21
82	Cell growth inhibition by a novel vitamin K is associated with induction of protein tyrosine phosphorylation. <i>Journal of Biological Chemistry</i> , 1998 , 273, 9906-11	5.4	42
81	Changes in TGF-beta receptors of rat hepatocytes during primary culture and liver regeneration: increased expression of TGF-beta receptors associated with increased sensitivity to TGF-beta-mediated growth inhibition 1998 , 176, 612		1
80	A phase II study of raltitrexed (Xomudex) in patients with hepatocellular carcinoma. <i>Annals of Oncology</i> , 1997 , 8, 500-2	10.3	20
79	Inhibition of spermidine synthase gene expression by transforming growth factor-beta 1 in hepatoma cells. <i>Biochemical Journal</i> , 1997 , 321 (Pt 2), 537-43	3.8	10
78	Quantitative assessment of the development of hepatoma in a buffalo rat model. <i>Transplantation Proceedings</i> , 1997 , 29, 2263-4	1.1	2
77	Gastrointestinal bleeding in cirrhotic patients with hepatocellular carcinoma undergoing intrahepatic artery chemotherapy. <i>Gastrointestinal Endoscopy</i> , 1997 , 46, 430-4	5.2	7

76	The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. <i>Hepatology</i> , 1997 , 26, 444-50	11.2	174
75	Recurrent hepatocellular carcinoma after liver transplantation: spectrum of CT findings and recurrence patterns. <i>Radiology</i> , 1996 , 198, 233-8	20.5	51
74	Hepatocellular carcinoma: evaluation with biphasic, contrast-enhanced, helical CT. <i>Radiology</i> , 1996 , 199, 505-11	20.5	317
73	Fine needle aspiration diagnosis of hepatocellular carcinoma in metastatic sites. <i>Acta Cytologica</i> , 1996 , 40, 443-9	3	17
72	The antiandrogen cyproterone acetate induces synthesis of transforming growth factor beta 1 in the parenchymal cells of the liver accompanied by an enhanced sensitivity to undergo apoptosis and necrosis without inflammation. <i>Hepatology</i> , 1996 , 23, 329-37	11.2	34
71	Comitogenic effects of vasoactive intestinal polypeptide on rat hepatocytes. <i>Journal of Cellular Physiology</i> , 1996 , 168, 141-6	7	10
70	Characterization of a human hepatoma cell line with acquired resistance to growth inhibition by transforming growth factor beta 1 (TGF-beta 1). <i>In Vitro Cellular and Developmental Biology - Animal</i> , 1995 , 31, 55-61	2.6	4
69	Growth inhibition of hepatoma cells induced by vitamin K and its analogs. <i>Journal of Biological Chemistry</i> , 1995 , 270, 28304-10	5.4	97
68	Differential display and cloning of messenger RNAs from the late phase of rat liver regeneration. <i>Biochemical and Biophysical Research Communications</i> , 1995 , 212, 21-6	3.4	16
67	Endothelin-1 expression by human hepatocellular carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 1995 , 216, 514-9	3.4	18
66	Identification of a human hepatocellular carcinoma-associated tumor suppressor gene by differential display polymerase chain reaction. <i>Life Sciences</i> , 1995 , 57, 1077-85	6.8	5
65	Integration of hepatitis B virus and alteration of the 1p36 Region found in cancerous tissue of primary hepatocellular carcinoma with viral replication evidenced only in noncancerous, cirrhotic tissue. <i>Hepatology</i> , 1995 , 22, 1393-1398	11.2	
64	Cell proliferation and oncogene expression after bile duct ligation in the rat: Evidence of a specific growth effect on bile duct cells. <i>Hepatology</i> , 1995 , 21, 1070-1078	11.2	2
63	The growth inhibitory effects of vitamins K and their actions on gene expression. <i>Hepatology</i> , 1995 , 22, 876-882	11.2	7
62	Differentially expressed genes in TGF-beta 1 sensitive and resistant human hepatoma cells. <i>Cancer Letters</i> , 1995 , 89, 73-9	9.9	26
61	Percutaneous ultrasound-guided needle biopsy of hepatic mass lesions using a cytohistologic approach. Comparison of two needle types. <i>American Journal of Clinical Pathology</i> , 1995 , 104, 583-7	1.9	14
60	Percutaneous fine-needle aspiration of portal vein thrombi as a staging technique for hepatocellular carcinoma. Cytologic findings of 46 patients. <i>Cancer</i> , 1995 , 75, 2057-62	6.4	33
59	Concomitant and isolated expression of TGF-alpha and EGF-R in human hepatoma cells supports the hypothesis of autocrine, paracrine, and endocrine growth of human hepatoma. <i>Journal of Surgical Oncology</i> , 1995 , 58, 240-5	2.8	38

58	Thioalkyl Derivatives of Vitamin K3 and Vitamin K3 Oxide Inhibit Growth of Hep3B and HepG2 Cells. <i>Bioorganic Chemistry</i> , 1995 , 23, 101-108	5.1	35
57	Detection of liver cells in peripheral blood of patients with advanced-stage hepatocellular carcinoma. <i>Hepatology</i> , 1995 , 21, 403-407	11.2	56
56	Cell proliferation and oncogene expression after bile duct ligation in the rat: Evidence of a specific growth effect on bile duct cells. <i>Hepatology</i> , 1995 , 21, 1070-1078	11.2	46
55	The growth inhibitory effects of vitamins K and their actions on gene expression. <i>Hepatology</i> , 1995 , 22, 876-882	11.2	67
54	Growth control and gene expression in a new hepatocellular carcinoma cell line, Hep40: inhibitory actions of vitamin K. <i>Journal of Cellular Physiology</i> , 1995 , 165, 459-67	7	36
53	Transforming growth factor beta 1 selectively increases gene expression of the serine/threonine kinase receptor 1 (SKR1) in human hepatoma cell lines. <i>Cell Structure and Function</i> , 1994 , 19, 305-13	2.2	13
52	Stimulation of hepatocyte DNA synthesis by neurotensin. <i>Journal of Cellular Physiology</i> , 1994 , 158, 215-222		35
51	Glutamic acid potentiates hepatocyte response to mitogens in primary culture. <i>Journal of Cellular Physiology</i> , 1994 , 158, 365-73	7	10
50	Small-for-size liver transplanted into larger recipient: A model of hepatic regeneration. <i>Hepatology</i> , 1994 , 19, 210-216	11.2	51
49	Hepatocyte proliferation and gene expression induced by triiodothyronine in vivo and in vitro. <i>Hepatology</i> , 1994 , 20, 1237-1241	11.2	80
48	The use of granulocyte-macrophage colony-stimulating factor to enhance hematologic parameters of patients with cirrhosis and hypersplenism. <i>Journal of Hepatology</i> , 1994 , 21, 582-6	13.4	10
47	An assay for micrometastatic hepatocellular carcinoma. <i>Gastroenterology</i> , 1994 , 106, 264-7	13.3	17
46	Small-for-size liver transplanted into larger recipient: A model of hepatic regeneration 1994 , 19, 210		2
45	Percutaneous biopsy of portal vein thrombus: a new staging technique for hepatocellular carcinoma. <i>American Journal of Roentgenology</i> , 1993 , 161, 229-33	5.4	47
44	Mutation at codon 249 of p53 gene in a human hepatoblastoma. <i>Hepatology</i> , 1993 , 18, 566-569	11.2	24
43	The 11-year Pittsburgh experience with liver transplantation for hepatocellular carcinoma: 1981-1991. <i>Journal of Surgical Oncology</i> , 1993 , 3, 78-82	2.8	34
42	Regional cancer chemotherapy for advanced stage hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 1993 , 3, 100-3	2.8	11
41	In situ hybridization of albumin mRNA in normal liver and liver tumors: identification of hepatocellular origin. <i>Vigiliae Christianae</i> , 1993 , 64, 361-5	0.2	32

40	Neurotensin-amplification of DNA synthesis stimulated by EGF or TGF alpha in primary cultures of adult rat hepatocytes. <i>Cell Structure and Function</i> , 1993 , 18, 105-10	2.2	7
39	ENHANCEMENT BY NEUROPEPTIDE [OF DNA SYNTHESIS STIMULATED WITH EGF OR TGF] IN PRIMARY CULTURES OF ADULT RAT HEPATOCYTES. <i>Biomedical Research</i> , 1993 , 14, 169-176	1.5	
38	POTENTIATION OF HEPATOCYTE SENSITIVITY TO MITOGENS BY GLUTAMIC ACID IN PRIMARY CULTURE. <i>Biomedical Research</i> , 1993 , 14, 243-252	1.5	
37	Hepatic parenchymal perfusion defects detected with CTAP: imaging-pathologic correlation. <i>Radiology</i> , 1992 , 185, 149-55	20.5	100
36	Cell physiology of antisense TGF-beta oligomers in hepatoma cells. <i>Annals of the New York Academy of Sciences</i> , 1992 , 660, 315-7	6.5	1
35	Effects of rapamycin on cultured hepatocyte proliferation and gene expression. <i>Hepatology</i> , 1992 , 15, 871-7	11.2	52
34	Hepatic resection versus transplantation for hepatocellular carcinoma. <i>Annals of Surgery</i> , 1991 , 214, 221-8; discussion 228-9	7.8	492
33	Radiation therapy for primary carcinoma of the extrahepatic biliary system. An analysis of 63 cases. <i>Cancer</i> , 1991 , 68, 289-94	6.4	62
32	Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation. <i>Cancer</i> , 1991 , 68, 2095-100	6.4	212
31	p53 mutation in hepatocellular carcinoma after aflatoxin exposure. <i>Lancet, The</i> , 1991 , 338, 1356-9	40	387
30	Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. <i>Journal of Clinical Oncology</i> , 1990 , 8, 491-501	2.2	186
29	3-Deazaguanine: report of a phase I trial and drug-related cardiac toxicity. <i>Investigational New Drugs</i> , 1990 , 8, 369-76	4.3	1
28	Treatment of metastatic malignant melanoma with trimetrexate: a phase II study. <i>Medical and Pediatric Oncology</i> , 1990 , 18, 49-52		6
27	Hormonal manipulation of human hepatocellular carcinoma. A clinical investigative and therapeutic opportunity. <i>Journal of Hepatology</i> , 1990 , 11, 287-9	13.4	19
26	Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium. <i>Journal of Clinical Oncology</i> , 1989 , 7, 439-44	2.2	53
25	TGF beta gene transcription in normal and neoplastic liver growth. <i>Journal of Cellular Biochemistry</i> , 1989 , 39, 477-87	4.7	46
24	Heparin-binding growth factor type 1 (acidic fibroblast growth factor): a potential biphasic autocrine and paracrine regulator of hepatocyte regeneration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1989 , 86, 7432-6	11.5	183
23	Combination chemotherapy with cytosine arabinoside (Ara-C) and cis-diamminedichloroplatinum (CDDP) for squamous cancers of the upper aerodigestive tract. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1989 , 12, 494-7	2.7	8

22	Carcinogenicity and haemoglobin synthesis induction by cytidine analogues. <i>British Journal of Cancer</i> , 1988 , 57, 395-402	8.7	41
21	Etoposide (VP-16) and cytosine arabinoside in the treatment of relapsed small-cell lung cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1988 , 11, 499-501	2.7	0
20	Changes in Hepatocyte TGF β Receptors and Gene Expression during Normal and Neoplastic Liver Growth 1988 , 275-281		
19	The Hepatocarcinogen Hydroxy-acetylaminofluorene Causes Decreased Binding of Epidermal Growth Factor to Rat Hepatocytes in Primary Culture. <i>Annals of the New York Academy of Sciences</i> , 1987 , 494, 376-378	6.5	1
18	Herniated lumbar disc disease in patients with malignancy. <i>Journal of Clinical Oncology</i> , 1987 , 5, 667-71	2.2	4
17	High doses of prochlorperazine for cisplatin-induced emesis. A prospective, random, dose-response study. <i>Cancer</i> , 1987 , 60, 2165-9	6.4	21
16	The Analysis of Carcinogen-Induced Pleiotropic Drug Resistance in Rat Hepatocytes 1987 , 215-239		
15	Experimental chemical hepatocarcinogenesis: early membrane changes of significance for drug resistance. <i>Journal of Cellular Physiology</i> , 1986 , 4, 59-63	7	
14	Binding of growth hormone to rat liver during experimental chemical hepatocarcinogenesis. <i>Endocrinology</i> , 1986 , 118, 1869-71	4.8	6
13	Chronic treatment with phenobarbital decreases the expression of rat liver EGF and insulin receptors. <i>Biochemical and Biophysical Research Communications</i> , 1986 , 135, 501-6	3.4	21
12	Pilot phase II trial of amphotericin B and CCNU in renal and colorectal carcinomas. <i>European Journal of Cancer & Clinical Oncology</i> , 1986 , 22, 329-30		4
11	High-dose continuous infusion folinic acid and bolus 5-fluorouracil in patients with advanced colorectal cancer: a phase II study. <i>Journal of Clinical Oncology</i> , 1986 , 4, 1058-61	2.2	32
10	DNA synthesis in rat hepatocytes: inhibition by a platelet factor and stimulation by an endogenous factor. <i>Journal of Cellular Physiology</i> , 1985 , 125, 82-90	7	59
9	Breast cancer with osseous metastasis and herniated lumbar disc. A cautionary tale. <i>Cancer</i> , 1985 , 56, 1701-3	6.4	3
8	The tumorigenicity of 5-azacytidine in the male Fischer rat. <i>Carcinogenesis</i> , 1984 , 5, 1583-90	4.6	125
7	Effects of the hepatocarcinogen 2-acetylaminofluorene on insulin binding to microsomal and Golgi fractions of rat liver cells. <i>Journal of the National Cancer Institute</i> , 1984 , 73, 505-9	9.7	8
6	Continuous five-day infusion of PALA and 5FU: a pilot phase II trial. <i>Medical and Pediatric Oncology</i> , 1983 , 11, 162-3		9
5	Renal carcinoma manifesting as breast mass. <i>Urology</i> , 1983 , 21, 166-7	1.6	5

4	Resistance to the cytotoxic effects of adriamycin is an early phenotypic change induced during hepatocarcinogenesis. <i>British Journal of Cancer</i> , 1981 , 44, 567-71	8.7	6
3	A liver colony assay for a new hepatocyte phenotype as a step toward purifying new cellular phenotypes that arise during hepatocarcinogenesis. <i>Annals of the New York Academy of Sciences</i> , 1980 , 349, 373-82	6.5	8
2	Antiemetic effect of intravenous diazepam in patients receiving cis-diamminedichloroplatinum II: a pilot study. <i>Medical and Pediatric Oncology</i> , 1979 , 7, 247-9		40
1	Critical overview of resection for Bismuth-Corlette type IV perihilar cholangiocarcinoma. <i>Acta Chirurgica Belgica</i> , 1-8	0.9	